Exploratory Study of MRI Biomarkers of NASH (IRM-NASH)

University Hospital, Angers

Status

Enrolling

Conditions

Non-alcoholic Fatty Liver Disease NAFLD

Treatments

Device: Quantitative MRI sequences

Study type

Interventional

Funder types

Other

Identifiers

NCT06626074

49RC23_0262

2024-A02056-41 (Other Identifier)

Details and patient eligibility

About

Metabolic steatosis disease (NAFLD) is a rapidly growing disease in the world, particularly in industrialized countries.

NAFLD is defined by the presence of fatty liver disease. This is a reversible phenomenon that can be estimated by non-invasive means, such as ultrasound. Non-invasive quantification, on the other hand, requires MRI.

Nonalcoholic steatohepatitis (NASH) is the aggressive form of the disease that promotes the accumulation of fibrosis in the liver, which can progress to cirrhosis and its complications.

Currently there is no non-invasive biomarker of NASH and the diagnosis is based solely on liver biopsy.

There is therefore a need for non-invasive biomarkers of NASH in patients with steatosis to diagnose NASH without the use of liver biopsy.

Enrollment

60 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient included in the SNIFF cohort of the Angers hospital where there is a suspicion of NASH requiring a biopsy for which an MRI is requested by a hepatologist as part of the initial assessment of the disease.
Adult patient
Free, informed and express (oral) consent of the patient to participate in the study

Exclusion criteria

Contraindication to MRI
Time between the establishment of the Steatosis/NASH status and the MRI greater than 3 months
Pregnant, parturient and breastfeeding woman
Person deprived of liberty by judicial or administrative decision
Person under compulsion to psychiatric care
Person subject to a legal protection measure
Person not affiliated or not covered by a social security scheme.